Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Return on Assets (2016 - 2025)

Historic Return on Assets for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to 1.13%.

  • Coherus Oncology's Return on Assets rose 8400.0% to 1.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.13%, marking a year-over-year increase of 8400.0%. This contributed to the annual value of 0.05% for FY2024, which is 4800.0% up from last year.
  • According to the latest figures from Q3 2025, Coherus Oncology's Return on Assets is 1.13%, which was up 8400.0% from 1.4% recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Return on Assets ranged from a high of 1.4% in Q2 2025 and a low of 0.61% during Q1 2023
  • Over the past 5 years, Coherus Oncology's median Return on Assets value was 0.31% (recorded in 2021), while the average stood at 0.02%.
  • Its Return on Assets has fluctuated over the past 5 years, first plummeted by -5600bps in 2021, then surged by 13300bps in 2024.
  • Coherus Oncology's Return on Assets (Quarter) stood at 0.4% in 2021, then plummeted by -40bps to 0.57% in 2022, then skyrocketed by 31bps to 0.39% in 2023, then surged by 339bps to 0.94% in 2024, then increased by 20bps to 1.13% in 2025.
  • Its Return on Assets stands at 1.13% for Q3 2025, versus 1.4% for Q2 2025 and 0.65% for Q1 2025.